CINtec® PLUS dual immunostain: A triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion

Diagnostic Cytopathology

Volumn 41, Issue 7, 2013, Pages 582-587

  Loghavi, Sanam ^a   Walts, Ann E ^a   Bose, Shikha ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

CINtec PLUS; HPV; Ki 67; p16; Pap smear

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16;

ADOLESCENT; ADULT; AGED; ARTICLE; CYTOPATHOLOGY; FEMALE; FOLLOW UP; GYNECOLOGICAL AND OBSTETRIC DIAGNOSTIC DEVICE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TRIAGE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84879410746     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22900     Document Type: Article

References (21)

1. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR,. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American pathologists interlaboratory comparison program in cervicovaginal cytology. Archives of pathology and laboratory medicine 2004; 128: 1224-1229.
2. Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355.
3. Cox JT, Schiffman M, Solomon D,. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406-1412.
4. Wright JD, Rader JS, Davila R, et al. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol 2006; 107: 822-829.
5. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006; 98: 92-100.
6. Cuschieri K, Wentzensen N,. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prevent 2008; 17: 2536-2545.
7. Wentzensen N, von Knebel Doeberitz M,. Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 315-330.
8. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R,. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010; 134: 12-21.
9. Guo M, Hu L, Baliga M, He Z, Hughson MD,. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2004; 122: 894-901.
10. Holladay EB, Logan S, Arnold J, Knesel B, Smith GD,. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer 2006; 108: 451-461.
11. Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K,. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: Correlation with biopsy follow-up results. Cancer 2007; 111: 83-92.
12. Schledermann D, Andersen BT, Bisgaard K, et al. Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up. Diagn Cytopathol 2008; 36: 453-459.
13. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prevent 2008; 17: 3033-3042.
14. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T,. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: A comparative study using simultaneously sampled histology materials. Cancer 2004; 102: 100-108.
15. von Knebel Doeberitz M,. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229-2242.
16. Nam EJ, Kim JW, Hong JW, et al. Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 2008; 19: 162-168.
17. Schmidt D, Bergeron C, Denton KJ, Ridder R,. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: Results from the European equivocal or mildly abnormal papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-166.
18. Cervista TM,. HPV HR [Package Insert]. Madison, WI: Third Wave Technologies; 2009.
19. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
20. Singh M, Mockler D, Akalin A, Burke S, Shroyer A, Shroyer KR,. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma. Cancer Cytopathol 2012; 120: 26-34.
21. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-509.